Oncopeptides AB (publ) (ONCOs)
Market Closed
CBOE 
- Market Cap
- P/E Ratio
- Div Yield
- Volume
0 Eps
Want to track ONCOs and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ONCOs is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
Oncopeptides AB (publ) (ONCOs) FAQ
On which exchange is it traded?
Oncopeptides AB (publ) is listed on CBOE.
What is its stock symbol?
The ticker symbol is ONCOs.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Oncopeptides AB (publ) ever had a stock split?
No, there has never been a stock split.
Oncopeptides AB (publ) Profile
| Biotechnology Industry | Healthcare Sector | Dr. Jakob Lindberg Med. Lic CEO | CBOE Exchange | SE0009414576 ISIN |
| Sweden Country | 63 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Oncopeptides AB (publ) stands out as a pioneering biotech entity, dedicated primarily to the commercialization, alongside the research and development of pioneering treatments aimed at combating hematological diseases, which are notoriously challenging to treat. The company showcases a global operational footprint, effectively extending its services across the United States, Europe, and other international markets. Established in the year 2000, Oncopeptides AB (publ) anchors its corporate headquarters in Stockholm, Sweden, marking a significant presence in the biotechnology sector, with a focused commitment towards addressing the unmet needs in the treatment of severe hematological conditions.
Products and Services
- Melflufen -- Melflufen represents the flagship product candidate from Oncopeptides AB (publ), designated specifically for the treatment of relapsed refractory multiple myeloma among adult patients. This particular therapeutic agent is distinguished as a drug conjugate, which underpins the company's innovative efforts in the complex field of oncology treatments. Melflufen's strategic development and proposed application underscore Oncopeptides AB's concentrated endeavor in advancing treatment options for multiple myeloma, a domain characterized by significant patient need.
Contact Information
Address: Vastra Tradgardsgatan 15
Phone: 46 86 15 20 40
Website: https://www.oncopeptides.com/sv
